NEW: Chelating RLT Peptides & Radiosensitizers! 

We are adding a new product line to our catalog: off-the-shelf and ready-to-use peptides for your basic and clinical cancer research! 

Chelating RLT Peptides: JPT offers Radioligand Precursors 

Radioligands are critical in many medical applications, particularly in targeted cancer diagnosis (molecular imaging) and treatment. These radioligands are selected for their specificity and pharmacokinetics. 

As the name suggests, radioligand therapy (RLT) makes use of a radioactive cationic metal (e.g. 177Lu, 68Ga or 64Cu) bound to a chelating agent such as DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or HBED (N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid), which is then attached to a peptide.This peptide typically targets a somatostatin or other endocrine receptor. Cyclic peptides have also been valuable ligands for over a decade due to their targeting and pharmacokinetic properties. 

JPT offers deep expertise in chelating peptide manufacturing, with both off-the-shelf and custom solutions. We provide excellent radioligand peptide precursors (without the metal) for your oncological research projects!  

Discover our NEW ready-to-use chelating precursor peptides: 

At JPT Peptide Technologies, we are adding new products to our range of high-affinity DOTA and NOTA precursor peptides specifically designed for somatostatin receptors, which are commonly found on neuroendocrine tumors. The chelating peptides are precursor peptides for prostate specific membrane antigen (PSMA) specific radio ligands. For research use only! 

• DOTA-NOC
• DOTA-TATE 
• DOTA-TOC 
• PSMA I&T 
• PSMA-11 
• Or choose a custom option! 

Take a look at our list of chelating peptides! 

Radiosensitizers 

Cancer cells that are initially sensitive to radiation therapy adapt over time, developing evading mechanisms that allow them to survive subsequent radiation treatments. Mechanisms include genetic mutations, change in DNA repair pathways, an altered cell cycle or increase antioxidant defenses. One such example is the activation of the NF-κB pathway in tumors, promoting the expression of anti-apoptotic proteins (e.g. Bcl-2, survivin) and DNA repair enzymes. 

This is where our peptides come in: a class of radiosensitizers, such as SN50 and SN52, are a promising new tool to overcome said limitations by inhibiting the NF-kB pathway. For research use only! 

• NF-kB Inhibitor SN50 - Translocation Inhibitor 
• NF-kB Inhibitor SN52 - Translocation Inhibitor
• Or choose a custom option!   

Benefits of working with JPT 

• 20 years of expertise: we ensure that every peptide we produce meets the highest standards of quality and performance 
• Innovation: pioneers in patented technologies for peptide libraries, pools, and microarrays, and other peptide tools 
• Unique capacities: with manufacturing capacities of more than 1 million peptides annually, JPT can support largest projects 
• Comprehensive support of your projects: Let us help you achieve your research and clinical goals with our superior peptide solutions 

Do you have any more questions? 

Reach out! Our team of experts is always here to support your research needs. Contact us today to inquire about our peptide tools or send us a quote request for custom options!